Bicara Therapeutics Inc. logo

Bicara Therapeutics Inc.

2023658

Bicara Therapeutics is a biotechnology company focused on developing innovative cancer therapies. They leverage a bifunctional antibody technology platform to design novel drugs that target both tumor cells and the tumor microenvironment. Their goal is to create more effective and durable treatments for patients battling various cancers.

86
Altamente Confiable
Puntuación de Confianza

Registro Oficial

Nombre Legal
Bicara Therapeutics Inc.
Número de organización
2023658
Estado de la Empresa
Active

Análisis de Calidad IA

Industria
Biotechnology
SSL/HTTPS
Seguro
Correo profesional
Correo de contacto
n.a.web.queries@computershare.com

🌟 Empresas similares de confianza

Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc. logo
71/100 · Confiable

Protalix is dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with their ProCellEx® plant cell-based expression system. They focus on treating rare diseases and have already launched two enzyme replacement therapies. The company is known for its innovative ProCellEx® technology.

Estados Unidos
Ver perfil

Immunocore Holdings plc

Immunocore Holdings plc logo
75/100 · Confiable

Immunocore Holdings plc pioneers TCR therapy, aiming to improve outcomes for patients with cancer, infectious, and autoimmune diseases. They develop transformative immunomodulating medicines using their ImmTAX technology. This technology activates the immune system to recognize and destroy diseased cells.

Estados Unidos
Ver perfil

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. logo
71/100 · Confiable

PacBio provides advanced DNA sequencing solutions, including Revio, Vega, and Onso systems. They are known for their HiFi long-read and SBB short-read technologies, used in research across human, plant, and microbial genomics. The company is positioned as a leading provider for precise and comprehensive genetic analysis.

Estados Unidos
Ver perfil